Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy ...
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS Imatics N.V. (NASDAQ: IMTX) has announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapy. The data will be presented at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain. The IMA 402 data will also be presented in a rapid oral presentation (1955RO) by Dirk Schadendorf, M.D., and the IMA 203CD8 data were presented in an oral presentation by Antonia Busse, M., at the ESMO meeting. The clinical profile of IMA400 indicates its potential as an off-the-shelf treatment option for patients with advanced PRAME-positive cancers. As of the data cutoff on June 1, 2026, 126 heavily pretreated patients across multiple tumor types, primarily melanoma and ovarian cancer, received at least one infusion of Ima402 during the dose escalation or dose expansion part of the ongoing trial. The efficacy population included 40 patients treated within the recommended Phase 2 dose (RP2D) range of 10 to 45 mg across varying PRAME expression levels. Safety was consistent across all doses, with no additive toxicity observed when combined with an immune checkpoint inhibitor (ICI). The most frequent treatment-related adverse events (TRAEs) were expected, and no cases of ICANS were reported.
Publicerad : 5 timmar sedan förbi https://immatics.com/ - (GLOBE NEWSWIRE) i Business Health
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage prog... [16811 symbols]
Ämnen: Biotechnology
